Product Name | MF | CAS | Details |
---|
Palonosetron Hydrochloride | C19H25ClN2O | 135729-62-3 | Details |
Ruxolitinib | C17H18N6 | 941678-49-5 | Details |
2,2',4',5'-tetrachloroacetophenone | C8H4Cl4O | 1201-42-9 | Details |
Cabotegravir ;GSK744;GSK1265744 | C19H17F2N3O5 | 1051375-10-0 | Details |
4-iodo-3,5-diMethylbenzaMide | C9H10INO | 1206679-91-5 | Details |
Ibrutinib impurity 7 | C25H26N6O2 | 1839099-22-7 | Details |
2-Acetamido-2-deoxy-b-D-thioglucopyranose | C8H15NO5S | 781581-10-0 | Details |
Sitagliptin Impurity | C16H17F4N5O | 945261-46-1 | Details |
Dimethyl (2E)-4-oxopent-2-enedioate | C7H8O5 | 78939-37-4 | Details |
Rocuronium Bromide EP Impurity G | C27H46N2O3 | 119302-20-4 | Details |
Aprepitant EP Impurity B | C29H25F7N4O3 | 2348441-62-1 | Details |
SB 204741 | C14H14N4OS | 152239-46-8 | Details |
LevetiracetaM IMpurity B | C8H12N2O2 | 358629-47-7 | Details |
Levetiracetam impurity 5 | C9H17NO4 | 1543300-90-8 | Details |
Folinic Acid EP Impurity D | C20H23N7O7 | Details |
Treosulfan | C6H14O8S2 | 299-75-2 | Details |
Rocuronium bromide | C32H53BrN2O4 | 119302-91-9 | Details |
Ethyl α-(p-Methoxyphenyl)-β-(dimethylamino)propionate | C14H21NO3 | 323176-93-8 | Details |
Aprepitant EP Impurity A | C23H22F6N4O3 | 170729-76-7 | Details |
FCE 28073 | C17H19FN2O2 | 174756-44-6 | Details |
Gefitinib IMpurity 1 | C15H22ClN3O3 | 1561173-24-7 | Details |
Mirabegron Deshydroxy | C21H24N4OS | 1581284-82-3 | Details |
Sitagliptin Impurity 22 | C26H23F9N6O2 | 2072867-07-1 | Details |
Levetiracetam impurity 2 | C8H17N3O2 | 1341459-52-6 | Details |
Elagolix Sodium impurity3 | Details |
(E)-4-(Dimethylamino)but-2-enoic acid | C6H11NO2 | 149586-32-3 | Details |
Vecuronium Bromide EP Impurity D | C30H53BrN2O2 | 73319-30-9 | Details |
5,10-METHYLENETETRAHYDROFOLATE | C20H23N7O6 | 3432-99-3 | Details |
Montelukast EP Impurity A | C35H37ClNNaO3S | 190078-45-6 | Details |
(R,S)-Palonosetron Hydrochloride | C19H25ClN2O | 135755-51-0 | Details |
(S,R)-Palonosetron Hydrochloride | C19H25ClN2O | 135729-76-9 | Details |
Guanine | C5H5N5O | 73-40-5 | Details |
LevetiracetaM IMpurity 4 | C10H19NO4 | 1342229-32-6 | Details |
Rocuronium Bromide EP Impurity F | C34H55BrN2O4 | 1190105-66-8 | Details |
LevetiracetaM IMpurity 3 | C8H15NO4 | 1543353-92-9 | Details |
6-O-dodecanoyl-methyl-α-D-glucopyranoside | C19H36O7 | 20869-08-3 | Details |
Salidroside | C14H20O7 | 10338-51-9 | Details |
Vecuronium bromide | C34H57BrN2O4 | 50700-72-6 | Details |
9-α-D-Ribofuranosyl-9H-purin-6-amine | C10H13N5O4 | 5682-25-7 | Details |
Sitagliptin Impurity | C16H17F4N5O | 945261-47-2 | Details |
Palonosetron Enantiomer | C19H24N2O | 135729-75-8 | Details |
N-METHYLBARBITURIC ACID | C5H6N2O3 | 2565-47-1 | Details |
1-[2-fluoro-6-(trifluoromethyl)benzyl]-5-iodo-6-methylpyrimidine-2,4(1H,3H)-dione | C13H9F4IN2O2 | 1150560-54-5 | Details |
D,L-N,N-Didesmethyl-N-(4-methoxyphenethyl) Venlafaxine | C24H33NO3 | 1329795-88-1 | Details |
Impurity B of Calcitriol | C27H44O3 | 66791-71-7 | Details |
Urea, N,N'-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]- | C29H32N6O9 | 1365267-35-1 | Details |
Ozanimod | C23H24N4O3 | 1306760-87-1 | Details |
N-[1-(2,3-DIOLEYLOXY)PROPYL]-N,N,N-TRIMETHYLAMMONIUM CHLORIDE | C42H80ClNO4 | 132172-61-3 | Details |
Trelagliptin Impurity 5 | C22H24FN5O5 | 2087874-92-6 | Details |
Levetiracetam impurity 1 | C8H16N2O3 | 1342566-28-2 | Details |
(R)-(4-(1-(2-cyano-1-cyclopentylethyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate | C23H28N6O2 | 1146629-80-2 | Details |
3,4-DI-O-ACETYL-6-DEOXY-L-GLUCAL | C10H14O5 | 34819-86-8 | Details |
2-AMINO-4-CHLORO-5H-PYRROLO[3,2-D]PYRIMIDINE | C6H5ClN4 | 943736-58-1 | Details |
D-Folic Acid | C19H19N7O6 | 65165-91-5 | Details |
3,5-Dihydroxyacetophenone | C8H8O3 | 51863-60-6 | Details |
Thiamet G | C9H16N2O4S | 1009816-48-1 | Details |
11-cis,13-cis-Retinoic Acid | C20H28O2 | 3555-80-4 | Details |
pre-Calcitriol PTAD Adduct | C35H49N3O5 | 86307-44-0 | Details |
(3S)-N-[[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]Methyl]-1-azabicyclo[2.2.2]octan-3-aMine | C18H26N2 | 177793-80-5 | Details |
Sitagliptin Impurity 27 | C22H24F6N4O2 | 1608491-98-0 | Details |
Sitagliptin impurity 2 | C16H17F4N5O | 945261-45-0 | Details |
Elagolix Sodium impurity4 | C19H21NO4S | 2248628-92-2 | Details |
Zolpidem Impurity 1 | C19H21N3O | 1346600-85-8 | Details |
N,N-DIMETHYL-2-NITROANILINE | C8H10N2O2 | 610-17-3 | Details |
Rocuronium Bromide EP Impurity A | C29H48N2O4 | 119302-24-8 | Details |
Folinic Acid EP Impurity H | C20H23N7O7 | 68538-85-2 | Details |
Dolutegravir;GSK1349572 | C20H19F2N3O5 | 1051375-16-6 | Details |
Rocuronium Bromide EP Impurity E | C32H53BrN2O3 | 1190105-65-7 | Details |
2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile | C7H10N2O2S | 1187595-85-2 | Details |
(R)-3-Piperidinamine dihydrochloride | C5H13ClN2 | 334618-23-4 | Details |
Tedizolid Impurity 3 | C17H16FN6O6P | 1835340-19-6 | Details |
(4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate | C22H27N7O4S | 1187595-90-9 | Details |
Eplerenone Impurity 19 | C24H30O7 | 209253-73-6 | Details |
2,16-Dipiperidin-1-ylandrosta-3,17-diol | C29H50N2O2 | 13522-16-2 | Details |
Elagolix Sodium impurity1 | Details |
Imatinib mesylate | C30H35N7O4S | 220127-57-1 | Details |
Primeverose | C11H20O10 | 26531-85-1 | Details |
Baricitinib phosphate salt | C16H20N7O6PS | 1187595-84-1 | Details |
Eplerenone EP Impurity A | C23H28O5 | 209253-67-8 | Details |
Trelagliptin Impurity I | C31H28F2N8O4 | 1917324-13-0 | Details |
Diphosphoric acid P,P'-bis[[(5R)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] ester | C34H30F2N12O11P2 | 1220910-90-6 | Details |
3-[(2R)-2-Amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-2,4(1H,3H)-pyrimidinedione | C28H24F5N3O3 | 830346-50-4 | Details |
Eplerenone Impurity 12 | C24H29NO5 | 192704-54-4 | Details |
Gefitinib Impurity 35 | C15H20N2O6 | 861453-12-5 | Details |
Fulvestrant impurity 5 | C32H45F5O3S | 2170200-14-1 | Details |
4-OXO-ISOTRETINOIN | C20H26O3 | 71748-58-8 | Details |
Ruxolitinib phosphate | C17H21N6O4P | 1092939-17-7 | Details |
Montelukast Dicyclohexylamine Salt | C47H59ClN2O3S | 577953-88-9 | Details |
Baricitinib | C16H17N7O2S | 1187594-09-7 | Details |
Mirabegron Impurity | C26H28N6O3S2 | 1684452-83-2 | Details |
DL-3-(1,2-Dihydro-2-oxo-quinoline-4-yl)alanine hydrochloride | C12H13ClN2O3 | 4876-14-6 | Details |
2-cyano-5-fluorobenzylbroMide | C8H5BrFN | 421552-12-7 | Details |
Elagolix Sodium impurity5 | Details |
6-HYDROXYURIDINE | C9H12N2O7 | 19556-63-9 | Details |
(5E)-Calcipotriene | C27H40O3 | 113082-99-8 | Details |
Elagolix Sodium | C32H29F5N3NaO5 | 832720-36-2 | Details |
5-(2-Fluoro-3-methoxyphenyl)-1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-2,4(1H,3H)-pyrimidinedione | C20H15F5N2O3 | 1150560-59-0 | Details |
Eplerenone EP Impurity D | C23H28O6 | 209253-82-7 | Details |
(2b,3a,16b,17b)-2,16-Bispiperidino-3,17-diacetoxy-5-androstane | C33H54N2O4 | 13529-31-2 | Details |
Elagolix Sodium impurity2 | 834153-88-7 | Details |
Product Total: Product Page: | ||||
1 2 3 |